Replies to post #177378 on Biotech Values

[DewDiligence]

PFE sweetens offer for AZN to a nominal value of $84.47/sh in cash and stock:

http://www.sec.gov/Archives/edgar/data/78003/000119312514178553/d718639dex991.htm

AstraZeneca shareholders would receive, for each AstraZeneca share, 1.845 shares in the combined company and 1,598 pence in cash, representing an indicative value of £50.00 ($84.47) per share…(on the basis of Pfizer’s closing share price of $31.15 (and an exchange rate of $1.00:£0.5919) on 1 May 2014).